For the year ending 2025-12-31, BICX had $51,327 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -3,508,763 |
| Depreciation and amortization | 44,003 |
| Amortization of discount on royalty obligation | 477,436 |
| Amortization of debt discount | 55,738 |
| Amortization of right-of-use asset | 40,056 |
| Loss on settlement of debt | -187,514 |
| Change in fair value of upfront purchase price liability | 7,426 |
| Change in fair value of royalty liability | -279,511 |
| Other income | 0 |
| Stock based compensation | 592,604 |
| Imputed interest for related party advances | 36,376 |
| Warrants issued in connection with the sales representative agreement | 4,430 |
| Accounts receivable | 253,459 |
| Grant receivable | 52,026 |
| Inventory | 9,828 |
| Prepaid expenses | 32,137 |
| Accounts payable and accrued expenses | 286,839 |
| Deposits | 0 |
| Upfront purchase price liability | -357,364 |
| Lease liability | -40,057 |
| Deferred revenue | 0 |
| Deferred revenue, grant | -56,590 |
| Net cash used in operating activities | -2,298,291 |
| Proceeds from common stock subscription and royalty agreement | 1,879,110 |
| Payment to economic injury disaster loan | 1,492 |
| Payment of notes payable - related party | 525,700 |
| Payment of notes payable | 150,000 |
| Proceeds from notes payable | 0 |
| Proceeds from notes payable - related party | 1,147,700 |
| Net cash provided by financing activities | 2,349,618 |
| Net increase (decrease) in cash | 51,327 |
| Cash, beginning of the year | 88,033 |
| Cash, end of the year | 139,360 |
BioCorRx Inc. (BICX)
BioCorRx Inc. (BICX)